Literature DB >> 18398728

DNA methyltransferase inhibitors: class effect or unique agents?

Elizabeth A Griffiths1, Steven D Gore.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18398728     DOI： 10.1080/10428190801947575

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  5 in total

Review 1.  Current therapy of myelodysplastic syndromes.

Authors:  Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal:  Blood Rev       Date:  2013-07-27       Impact factor: 8.250

2.  A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.

Authors:  Paul W Hollenbach; Aaron N Nguyen; Helen Brady; Michelle Williams; Yuhong Ning; Normand Richard; Leslie Krushel; Sharon L Aukerman; Carla Heise; Kyle J MacBeth
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

Review 3.  Epigenetic changes in gliomas.

Authors:  Rebecca Burgess; Robert Jenkins; Zhiguo Zhang
Journal:  Cancer Biol Ther       Date:  2008-09-18       Impact factor: 4.742

4.  Epigenetic drug 5-azacytidine impairs proliferation of rat limb buds in an organotypic model-system in vitro.

Authors:  Vedrana Muzic; Ana Katusic Bojanac; Gordana Juric-Lekic; Marta Himelreich; Katarina Tupek; Ljiljana Serman; Nina Marn; Nino Sincic; Maja Vlahovic; Floriana Bulic-Jakus
Journal:  Croat Med J       Date:  2013-10-28       Impact factor: 1.351

Review 5.  Histone deacetylases as targets for antitrypanosomal drugs.

Authors:  Aline A Zuma; Wanderley de Souza
Journal:  Future Sci OA       Date:  2018-07-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.